On June 16, 2017, 107,330,210 Idorsia shares were listed on SIX (symbol: IDIA). Furthermore, shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson (CHF 135.4 million converting into 11,793,220 Idorsia shares “Authorized Shares”) were listed on June 20, 2017 granting Cilag Holding AG an ownership interest of 9.9% in Idorsia’s share capital.
On July 13, 2018 the Group privately placed 11,912,000 new registered shares of CHF 0.05 par value from existing authorized capital at CHF 25.62 per new share receiving gross proceeds of CHF 305 m through an accelerated bookbuilding. The newly issued shares corresponded to approximately 10% of the Group’s currently issued share capital.
Concurrently to the private placement of new shares, the Group issued CHF 200 m of senior unsecured convertible bonds (“the Bonds”) on July 17, 2018. The Bonds mature on July 17, 2024 and are convertible into 5.9 m registered shares of the Group, sourced from existing conditional share capital, on or after August 27, 2018. The Bonds have a coupon of 0.75% and a conversion price of CHF 33.95, corresponding to a conversion premium of 32.5% above the bookbuilding price of the privately placed newly issued shares.
Idorsia Ltd is part of the following indices: SPI, SPIEX, SXSLI, SXI Life Sciences, and SXI Bio+Medtech.
Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA.
Key Share Data
| As of 30 September 2018 | |
| Shares outstanding | 131.0 million |
| Closing share price | 24.72 CHF |
| Market capitalization | 3,240 million CHF |
| 52-week high | 30.70 CHF |
| 52-week low | 17.10 CHF |
| YTD price change | -1.76 CHF (-6.65%) |
| HY Average daily volume | 340,234 shares |
| Free float | 74.29 million shares |
We will update this information quarterly.
Major Shareholders
As of 30 September 2018
| Shareholder | Position |
|
Martine and Jean-Paul Clozel |
>25% |
|
Johnson & Johnson Rudolf Maag |
>5% |
